Adjuvant Pembrolizumab Beneficial in Metastatic NSCLC

Share this content:
Adjuvant Pembrolizumab Beneficial in Metastatic NSCLC
Adjuvant Pembrolizumab Beneficial in Metastatic NSCLC

MONDAY, April 16, 2018 (HealthDay News) -- For metastatic non-small-cell lung cancer (NSCLC), the addition of pembrolizumab to standard chemotherapy is beneficial; and nivolumab plus ipilimumab is associated with better survival than chemotherapy for NSCLC with high tumor mutational burden, according to two studies published online April 16 in the New England Journal of Medicine to coincide with the annual meeting of the American Association for Cancer Research, held from April 14 to 18 in Chicago.

Leena Gandhi, M.D., from the NYU Perlmutter Cancer Center in New York City, and colleagues randomized 616 patients with metastatic nonsquamous NSCLC without sensitizing EGFR or ALK mutations to receive pemetrexed and a platinum-based drug plus either 200 mg of pembrolizumab or placebo. The researchers found that the estimated rate of overall survival was 69.2 and 49.4 percent, respectively, in the pembrolizumab-combination group and the placebo-combination group at 12 months (hazard ratio for death, 0.49).

Matthew D. Hellman, M.D., from the Memorial Sloan Kettering Cancer Center in New York City, and colleagues randomized patients with stage IV or recurrent NSCLC that was not previously treated to receive nivolumab plus ipilimumab, nivolumab monotherapy, or chemotherapy. The researchers found that patients with a high tumor mutational burden had significantly longer progression-free survival with nivolumab plus ipilimumab versus chemotherapy. The one-year progression-free survival rate was 42.6 versus 13.2 percent with nivolumab plus ipilimumab versus chemotherapy; median progression-free survival was 7.2 versus 5.5 months (hazard ratio for progression or death, 0.58).

"Progression-free survival was significantly longer with first-line nivolumab plus ipilimumab than with chemotherapy among patients with NSCLC and a high tumor mutational burden, irrespective of programed death liand-1 expression level," Hellman and colleagues write.

The Gandhi study was sponsored by Merck; the Hellman study was funded by Bristol-Myers Squibb and Ono Pharmaceutical.

Abstract/Full Text - Gandhi
Abstract/Full Text - Hellman
More Information

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Trending Activities

All Professions

Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

CDC: U.S. Abortion Rate Declined 24 Percent From 2006 to 2015

CDC: U.S. Abortion Rate Declined 24 Percent From ...

Abortions among women ages 15-44 fell 26 percent, from 15.9 to 11.8 abortions per 1,000 women

U of Maryland Student Dies of Adenovirus-Related Illness

U of Maryland Student Dies of Adenovirus-Related Illness

CDC testing of specimen revealed adenovirus type 7, a strain that may cause more severe illness

FDA Approves Drug to Treat Rare Immune Disease

FDA Approves Drug to Treat Rare Immune Disease

Gamifant first drug to be approved specifically for primary hemophagocytic lymphohistiocytosis

is free, fast, and customized just for you!




Already a member?

Sign In Now »